Linxens

122 rue Edouard Vaillant
92300 Levallois Perret, France
92300, 
France
https://www.linxens.com/
  • Booth: 3289

Linxens is a global manufacturer of flexible electronics & a trusted CDMO for connected health solutions. Linxens designs & manufactures electrochemical biosensors & stick-to-skin wearables for healthcare applications. Linxens is capable to develop, customize & scale-up products with a proven track records of hundreds of millions of biosensors & tens of millions of smart patches. Located in France with 9 production sites, 5 R&D centers with 3,000 people worldwide. Visit: https://www.linxens.com/


 Press Releases

  • Strong transformations have happened in recent years. Covid outbreak had a tremendous impact on our lives and our practices, encouraging and accelerating technological and social changes at many levels. Most obvious is of course teleworking and home delivery as response to lock down and travel restrictions, but it has also modified our perception of medical innovations that was already happening in healthcare, all looking after the same objective: avoid unnecessary visits to hospital and physicians to reduce occupation and face medical staff reduction.

    Markets are already moving on with these technologies. United States before anyone else, followed by Europe and Asia Pacific region. This is directly linked to the fact these regions are facing an ageing population with the challenge related to chronic diseases, and an increased awareness of infectious diseases.

    All-in-all, the benefits of the new wearable “smart-patches” are multiple and significant. Alix Joseph, New Ventures HealthCare Director at Linxens have listed 5 major benefits to both clinicians, patients and society:

    1. Continuous monitoring: Unlocking easy continuous monitoring of various physiological parameters such as heartbeat, temperature or breathing (but not only), it provides a complete picture of patients’ vital signs, not only a snapshot.
    2. Remote monitoring: Connected to smartphones or other devices, they allow patients to send data to healthcare providers remotely. This can help to identify problems early and improve the management of chronic conditions.
    3. Early detection: Continuous monitoring allows for early detection of changes in patients' health leads to early treatment and then better outcomes.
    4. Personalized medicine: Monitoring and tracking individual patients' health metrics, providing valuable information could be used to develop personalized treatment plans.
    5. Cost-effective: Being disposable and less expensive than other traditional medical devices and lab tests, it makes them more accessible for patients and healthcare providers.

    Linxens is working on the vertical integration of the different pieces in these wearable medical devices to ensure the easier and faster development, focusing on robust and reliable solutions. The expertise gained in the past decades in mass production for flexible electronics leads to a unique capacity to propose cost-effective complex solutions for medical partners, both for biosensors, design, converting and secured data transfer.

    If you wish to discuss with Alix Joseph, New Ventures HealthCare Director at Linxens, do not hesitate to contact us.

    To donwload the press release

    Press contact: Agence Elektron

    Alicja Prod’homme / +33 6 50 17 54 91 / alicja@elektron-presse.com

    Camille Gachet / +33 6 84 34 74 70 / camille@elektron-presse.com

  • Rapid and comprehensive Point-of-Care Testing solution for critical care 

    In critical care - intensive care units, emergency departments, operating rooms or neonatology units - fast turnaround time for diagnostic test results have been correlated to improved patient outcomes. The ability to rapidly analyze a range of basic biomarkers in patient blood can be vital.

    Siemens Healthineers’ FDA and Health Canada approved epoc® Blood Analysis System, a so-called BGEM analyzer, was designed to specifically address these critical requirements.
    It enables fast comprehensive analysis of blood gases (ie, pH, pCO2, pO2), electrolytes (ie, Na+, K+, Ca2+, Cl-), metabolites (ie, Glucose, Lactate, Urea, Creatinine)
    and Haematocrit. It is a patient-side testing solution that delivers a full menu of laboratory-accurate tests in less than a minute.

    Image Epoc Card

    A mini, portable laboratory that tests 13 parameters simultaneously

    The epoc system combines a reader and a single use Test Card (see figure 1). The Test Card is an electrochemical biosensor that incorporates an array of 14 electrodes (13 working and one reference), reagents, calibrators and microfluidic circuits. 

    When the Test Card is inserted into the reader, after a drop of blood has been placed within the Test Card, the reagents deposited on the electrodes enable
    electrochemical reactions. The electroplated electrodes developed by Linxens, an alternative to standard Screen-Printed-Electrodes, also enable the reaction and capture the generated signals.

    These electrical signals are then analyzed by the reader. Laboratory-quality results are produced within a minute and immediately transmitted to the hospital
    information system through wireless protocols.


    Mathias Ganzmann Siemens Healthineers

    “The epoc system is a worldleading fully diagnostic tool which has transformed critical healthcare, by enabling doctors to provide the right care in a very short time. Linxens has been integral to the development of this Point-of-Care solution and our research and development teams continue to work closely together on next generation systems. The electrode array allows to
    perform 13 test parameters simultaneously with just one card whereas predicate devices need multiple cartridges. This helps to maximise hospital efficiency and reduce costs.”

    Mathias Ganzmann, General Manager of Siemens Healthineers


    Linxens unique processes for creating biosensors

    Linxens developed the electrodes which are the ‘sensing’ elements of the Siemens epoc® Test Card. The unique Linxens manufacturing process can be summarized with following few steps.
    Fourteen 0.75mm holes (or wells) are punched in a 110μm glass-epoxy substrate. A 35μm copper sheet is laminated on top of the substrate. It is then chemically etched to create the pattern of the connector side for electrical contact with the epoc reader. Finally, nickel and gold are electroplated on top of the copper on both sides. Thus, wells are formed and will receive in a latter process the reagents. The construction of the electrode array is an innovative feature. Linxens has manufactured hundreds of millions of electrode arrays for over 15 years, delivered in reel-to-reel format for cost-effective manufacturing of the Test Card. 


    Christelle Robelin

    “Linxens is proud of the long-standing relationship it has built with Siemens Healthineers, developing innovative biosensing solutions. The quality of our electrodes contributes to the excellent precision and accuracy of the tests. Quality is a high priority for Linxens, and we are proud that our French industrial site in Mantes-la-Jolie recently received the ISO 13485: 2016 certification for the design, industrialization, and manufacture of sub-components for medical devices. This will enable Linxens to accelerate its development in the health sector, and to continue supporting Siemens Healthineers on future developments.”

    Christelle Robelin, Healthcare Marketing Director, Linxens

    Linxens technologies used to manufacture hundreds of millions of epoc® Test Cards | Linxens

  • The Point-of-Care market is facing an increased need for mass volume solutions to generalize patient monitoring. Thanks to its reel-to-reel manufacturing and know-how capabilities, Linxens is able to design and manufacture high volumes solutions and to develop advanced transceiver electrochemical strip solutions. The Linxens electrodes’ response signal is stable and well-defined and demonstrates a great reversibility and stability over cycling in the presence of Ferrocene Methanol. In blanks, a stable signal is obtained between -0,3 to + 0,3 V vs Ag/AgCl in PBS, and between -0.3V to 1.5V vs Ag/AgCl in PB.

    Authors: 
    Youssef Ben M'Barek, Innovation Engineer 
    Simon Vassal, Innovation Manager

    Linxens electrodes are based on a complex yet well mastered process, allowing the high scale manufacturing of customer specific Flexible Printed Circuit Boards (FPCB) that have proven to be an excellent and cost-effective alternative to standard screen printed or sputtered electrodes.  

    We can summarize this process as follows: On a copper foil, the electrode’s design is patterned using a photolithographic process followed by a chemical etching. The resulting conductive traces can then be used as a seed layer on top of which a Nickel layer is electroplated. Then a functional gold layer is applied selectively to ensure the right coverage of the under layers on the sensing area while a thinner layer is deposited on the non-functional areas leading to a cost optimized design.

    Fig 1

    Linxens electrodes are made from stacks of different materials. Most substrates are comprised of polyimide 50µm or PET 150µm and a sheet of copper of 18 µm glued onto the substrate and chemically patterned to the desired design. A thick layer of nickel is electroplated of top of the copper and completed with a few hundred nanometers of gold.


    Linxens has been refining its electroplating technology recently to achieve a great command of the surface’s microstructure and purity, leading to a highly engineered product particularly suitable for electrochemical biosensing applications. Hereafter is an example of Linxens electrodes electrochemical behavior under different conditions.


    I – Electrochemical Response in the presence of 1mM Ferrocene Methanol (FeMeOH) in PBS:
    To assess the electrodes’ sensitivity and the quality of the electrons transfer to a redox probe, multiple CVs have been recorded using Linxens’ Open Tool 4 (OT4) as a working electrode, in the presence of FeMeOH.  A stable and well-defined signal is obtained, displaying a great reversibility and stability over cycling as shown on Fig.2 – (a). Moreover, using Randles Sevcik equation [1], the linear dependence of the peak current in function of the scan rate’s square root can be calculated, as demonstrated in Fig.2 – (b), with an R2 > 0.99.
     

    Fig 2

    The same experiment was performed using a commercial gold electrode and the recorded signal overlaid with the OT4’s CV as shown in Fig.3. Despite the price difference, the sensitivity of Linxens’ electrodes is similar to the massive gold ones (Metrohm/61204140), proving the former to be a great option when considering the high scale production of gold-based biosensors. Moreover, this CV was recorded using the OT4 without any cleaning pretreatment (no polishing, no chemical or physical treatment) and can serve as a proof for the quality of Linxens’ process, resulting in a pristine gold surface. 

    Fig 3

    II - Blank Cyclic Volammograms: 
    Since the presence of a redox probe can hide smaller signals, blank CVs were recorded in the presence of different electrolytes to assess the electrodes surface state. The results of the blank CV of two of the most used electrolytes in biological applications, Phosphate Buffer (PB) and Phosphate Buffer Saline (PBS) are presented in the diagrams a and b. It should be noted that performing blank CVs could alter the surface state, especially in the presence of non-innocent species such as chloride[2,3,4], as demonstrated in the following sections.
     

    a - Blanks in Phosphate Buffer (PB):

    Fig 4

    In PB, a noise free CV was recorded using OT4 as a working electrode, as can be observed in Fig.5. The typical oxidation and reduction peaks of a gold surface are obtained, and the signal remained stable over a wide potential range (from -0.3V to 1.5V vs Ag/AgCl). This stability in oxidative conditions is critical when designing electrochemical biosensors since most of the point of care applications occur at positive potential.

    It should be noted that, depending on the electrode design, a small signal (peak height in the uA range) can be observed around 0.2V vs Ag/AgCl, as shown in Fig.5 – (a). This signal is stable over cycling and this phenomenon will not lead to any degradation of the electrode. Nevertheless, this signal is stable over cycling and, if needed, it can be suppressed by a fine engineering of the electrode’s construction, as shown in Fig.5 – (b).
     

    Fig 5

    b - Blank in Phosphate Buffer Saline (PBS):

    The main difference between PB and PBS is the presence of chloride ions. As described in the literature, chloride affinity with gold can promote its dissolution through soluble complex formation when working at oxidative potentials, above +0,5 V vs Ag/AgCl[2,3,4]. It is advised to remain below this limit to avoid damaging Linxens’ electrodes and expose the under layers.

    Fig 6

    A stable signal is obtained between -0,3 to + 0,3 V vs Ag/AgCl in PBS. In the presence of chloride, a redox couple can be observed as shown in Fig.6 – (a). Similarly to the experiments performed in PB, the optimization of the electrode’s construction allows to modulate this signal, leading to a stable signal even in the -0.5V to 0.5V vs Ag/AgCl potential window as demonstrated in Fig.6 – (b).

    Conclusion:
    Overall, electrochemical biosensing is a fast-growing industry and Linxens products are able to match the market needs in a cost-effective way regarding the electrodes supply. One of the key advantages of Linxens’ process is its versatility which allows a fine control over the design, the materials and the construction of the electrodes towards developing a quality sensor at industrial level. One of the main concerns of electrochemists developing FPCB based point of care devices is the access to the underlayers. The above-mentioned experiments have demonstrated that Linxens’ electrodes response is stable in different supporting electrolytes and showed great reversibility and stability over cycling in the presence of FeMeOH. This is thanks to its electroplating process allowing to manufacture gold specific design electrodes suitable for biosensing applications.

    References:
    [1]. K.B. Oldham; J. Electroanal. Chem. 105 (1979) 373—375.
    [2]. S. Cherevko & al;  RSC Adv. 3 (2013), 16516-16527.
    [3]. D.R. Ramirez-Rico & al, J. Electrochem. Soc. 164 (2017) H994.
    [4]. B. Medgyes & al; Materials. 14 (2021), 5237.

    Linxens electrodes: A cost-effective & high-quality alternative to standard gold electrodes | Linxens

  • Opinion | How telemedicine could become the key to home care ? published in Les Echos (French)

    Guest column by Yvan Malépart, Senior Vice President Global Sales and Marketing, Linxens

    Telemedicine, or remote medical monitoring, allows a healthcare professional to remotely interpret the data needed to monitor a patient's health and, if necessary, take action to manage the patient. While this device is already well established in the United States, it is not yet as developed in Europe. After having been the subject of an experiment in France between 2014 and 2021, with the ETAPES program, remote monitoring was to become part of common law and thus be generalized by July 1, 2022 at the latest with the Social Security Financing Bill (LFSS). This decree, which will specify, among other things, the pricing and conditions of patient care, has finally been postponed to a later date.

    As the Forum Labo approaches, how do industry experts see the remote monitoring market evolving? 

    Remote medical monitoring, a growing market…

    The world, and the United States in particular, have an appetite for remote monitoring. Indeed, the amount of investments in digital health was 5 times higher in 2021 than in the rest of Medtech, with American investments being particularly active. The validation of a legislative framework should allow Europe to attract more investors. The postponement of the application of this decree is therefore a source of tension because many companies have an economic interest in remote monitoring, but also because it will lead to profound changes in patient care. 

    While it is true that Covid-19 has facilitated the adoption of these technologies by North American healthcare professionals, it is the long-term trends such as the scarcity of healthcare professionals, particularly specialists (this is likely to continue for another twenty years), the aging of the population and the explosion in the number of pathologies and chronic diseases, that will change the lines in France. Behind the acceleration of the implementation of these measures is the desire to change the healthcare system in order to relieve hospital overcrowding and provide access to care, particularly in medical deserts. 

    Companies have clearly understood that this is a market of the future and that with the entry into force in common law of the framework for the coverage of remote monitoring for the 4 chronic diseases that have the greatest impact on the healthcare system (diabetes, chronic heart failure, chronic renal failure and chronic respiratory failure), the potential is enormous.
     

    …And driven by start-ups

    Numerous start-ups are proposing well-developed technological solutions, but they are held back by the legislative lever that does not allow patients to be reimbursed. In addition, the creation of medico-economic data requires significant investments for these small structures. 

    However, the large groups are not left out. It is true that the latter are more easily attracted to hospital monitoring, but some of them have clearly understood the stakes behind remote home monitoring and are ready to take over the market. Their objective is to buy the most promising startups when the market is mature in order to accelerate the development of technologies. For both parties, this is a win-win agreement as these small structures will then benefit from the large network of the big groups. 

    At the same time, some large groups already offer their remote medical monitoring solutions without reimbursement codes and generate economic data for years before lobbying the health authorities to obtain them. To embark on such a project today requires a strong backbone. 


    While this is certainly a sector full of potential, the remote medical monitoring market is not yet structured. The entry of remote monitoring activities into common law will allow for the deployment of remote monitoring devices and therefore a growth in the market. This market will then consolidate and should allow start-ups to attract more investors and, for companies that are ready to market their solutions, to generate profits. However, it is important to remain cautious because this market can also be shaken if the legislative framework changes, as was the case in the United States in 2021 when the reimbursement rates for remote monitoring care were revised downwards. 


 Additional Info

We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
No
Included in the Export Interest Directory?
Yes
Business Needs:
Direct Sales
Countries of Interest
Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Hong Kong, India, Indonesia, Italy, Japan, Korea (South), Lebanon, Lithuania, Luxembourg, Malaysia, Netherlands, New Zealand, Philippines, Singapore, South Africa, Sweden, Switzerland, Taiwan, Thailand, United Arab Emirates, United Kingdom, United States, Vietnam